ISABEL CRISTINA ESPOSITO SORPRESO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Hormone therapy effect on menopausal systemic lupus erythematosus patients: a systematic review(2022) SOARES-JR, J. M.; SORPRESO, I. C. Esposito; CURADO, J. F. Nunes; FERREIRA FILHO, E. S.; SIMOES, R. dos Santos; BONFA, E.; SILVA, C. A.; BARACAT, E. C.Systemic lupus erythematosus (SLE) primarily affects women, who may need hormone therapy (HT) in menopause. There is, however, some concern as to its efficacy and safety. This systematic review aimed to determine the effect of HT on the activity of SLE and its safety. The study was a qualitative systematic review. Research was conducted with data retrieved from Embase, MEDLINE and Cochrane databases using MESH terms up to April 2021, with no bar on date or language. Sixteen studies were selected for analysis. Most of them showed HT to be effective in the treatment of menopausal symptoms with no impact in SLE activity, but one randomized clinical trial showed an increase in the number of thrombotic events. The present systematic review demonstrated the efficacy of HT for treating the menopausal symptoms of SLE patients. The risk of flare and thrombosis seems to be very low.
- Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report(2022) FERREIRA-FILHO, Edson Santos; BAHAMONDES, Luis; DUARTE, Daniele Coelho; GUIMARAES, Ana Lucia Monteiro; ALMEIDA, Patricia Goncalves de; SOARES-JUNIOR, Jose Maria; BARACAT, Edmund Chada; SORPRESO, Isabel Cristina EspositoIntroduction Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum. Given its teratogenic potential, it is essential that an effective contraceptive method is used, especially a long-acting reversible contraceptive (LARC) method. The subdermal etonogestrel (ENG)-releasing implant is an adequate method due to the high effectiveness and long-term use. However, interaction between thalidomide and ENG has not been well documented. Concern arises because thalidomide interacts with cytochrome P450 (CYP450) enzymes that metabolize sexual steroids. AIM: We aimed to study the effectiveness and safety of the ENG-implant in a thalidomide user. Methods Case report of a sexually active 21-year-old patient with both Hansen's disease and leprosy reaction type 2 treated with thalidomide requiring effective contraception. Follow-up was up to 36 months after implant placement. Results Contraception with ENG-implant was effective and safe, based on clinical parameters (reduction of menstrual flow and cervical mucus thickening) and laboratory parameters (gonadotropins and sexual steroids). Conclusion To the best of our knowledge, this is the first case reported which presents a patient in simultaneous use of thalidomide and ENG-implant. Although this case report preliminary supports effectiveness and safety of ENG-implant as a contraceptive option in women using thalidomide, rigorous drug-drug interaction research is needed to better characterize the interaction between thalidomide and the ENG-implant.
- Vulnerability in adolescence: A case report of attempted abortion and sexual violence(2017) SILVA, A. T. M. da; SOUSA, G. D. de; MENEZES, C. L.; FILHO, E. S. F.; PINHEIRO, W. da Silva; JUNIOR, J. M. S.; BARACAT, E. C.; SORPRESO, I. C. E.Introduction: Abortion, even when provided by law in cases of sexual violence, continues to be practiced in an insecure way, since women who suffer violence are not reported or guarded by social, institutional or age vulnerability, as in adolescence. Objective: Describe the clinical consequences of unsafe abortion, report this experience as well as sexual violence in situations of social and age vulnerability. Methods: It is a clinical case report, with the consent of the patient, in the year 2016, of a 16-year-old female adolescent with a personal history of sexual violence by an intimate aggressor. Admitted to the health service with diagnosis of acute abdomen and induced abortion using antibiotic therapy. Results: Laboratory tests revealed altered C reactive protein and presence of leukocytosis, ultrasound showed heterogenic mass, computed tomography showed presence of cylindrical foreign body in vaginal cavity, surgical interventions, sepsis, clinical complications (pulmonary thromboembolism) and prolonged hospitalization. Conclusion: The history of violence portrayed in this study reveals an attempt of abortion with self harm, revealing negative clinical repercussions and the health problems of the adolescent. This person has committed an abortion that does not fit into the abortion criteria provided by law. It also revealed the need for further discussion on the topic, highlighting health promotion practices against unsafe abortion.
- Contraception and reproductive planning during the COVID-19 pandemic(2020) FERREIRA-FILHO, Edson Santos; MELO, Nilson Roberto de; SORPRESO, Isabel Cristina Esposito; BAHAMONDES, Luis; SIMOES, Ricardo Dos Santos; SOARES-JUNIOR, Jose Maria; BARACAT, Edmund ChadaIntroduction The coronavirus disease (COVID-19) is a global health emergency. Major disruption to healthcare services during the current COVID-19 pandemic will last even after its peak. Sexual and reproductive health (SRH), specially contraception, needs to be understood as an essential service. Areas covered This paper is a narrative review. Data from PubMed/MEDLINE, Scopus, and websites of scientific societies were screened during the months of April and May 2020. It addresses the main aspects related to contraception during the COVID-19 pandemic, with special emphasis on family planning services, extended use of long-acting reversible contraceptive (LARC) methods, drug interactions, and thromboembolism risk. We also specified some issues focused on the Brazilian reality. Expert opinion Ensuring proper contraception use in the COVID-19 time is very important. We encourage women, healthcare providers, policymakers, and the society to consider SRH services as priority.
bookPart Anticoncepção para adolescente diabética(2021) JúNIOR, José Maria Soares; SORPRESO, Isabel Cristina Esposito; FERREIRA FILHO, Edson Santos; BARACAT, Edmund ChadabookPart Anticoncepção para adolescente moradora de rua(2021) SORPRESO, Isabel Cristina Esposito; ALMEIDA, Patrícia Gonçalves de; TAKIUTI, Albertina Duarte; FERREIRA FILHO, Edson Santos; JúNIOR, José Maria Soares; BARACAT, Edmund Chada- Factors Associated with Adolescents' Choice to Use Long Acting Reversible Contraceptives: a Systematic Review(2018) REIS, Yedda Nunes; VILELA, Ana Luiza; COSTA, Annielson de Souza; ANDRADE, Mayra Rayane Freire; FERREIRA FILHO, Edson Santos; ABREU, Luiz Carlos de; SOARES JUNIOR, Jose Maria; BARACAT, Edmund Chada; SORPRESO, Isabel Cristina EspositoPurpose of ReviewThis review aims to update the published literature to summarize our understanding about the associated factors with adolescents' willingness to use long-acting reversible contraceptives.Recent FindingsLong acting reversible contraception (LARCs), specifically intrauterine devices and implants, have been successful in preventing unintended pregnancy and repeat pregnancy among adolescents. Unfortunately, many misconceptions about eligibility, fears of the insertion procedure, and health effects prevent adolescents from choosing them.SummaryA total of 1316 articles were identified and only nine met the inclusion criteria. Included studies reported findings on 12,851 adolescents aged 12 to 19years old, revealing many correlates like the knowledge/information about these contraceptives, age, marital status, and cultural aspects. Few articles compared the correlates of choosing intrauterine devices versus implants. All articles presented studies performed in contexts where access barriers to contraceptives were removed, including the costs. In the future, it could prove useful to develop a study that could compare types of LARCs, as well as in an exclusive adolescent population in different countries. It would also be helpful to compare adolescents' use in low- and middle-income countries, and in different contexts with limited access to family planning services and contraceptives.